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Abstract.
Background: The detection of prodromal Parkinson’s disease (PD) is desirable to test drugs with neuroprotective potential,
but will be affected by known disease variations.
Objective: To assess the prevalence of four key non-motor prodromal PD markers, and evaluate the sensitivity of case
detection when non-motor screening tools for prodromal PD are implemented in an early clinical PD cohort.
Methods: Hyposmia (University of Pennsylvania smell identification test ≤15th centile or Sniffin’ Sticks at or ≤10th centile
corrected for age and sex), rapid-eye movement sleep behaviour disorder (RBD questionnaire >4), constipation (<1 daily
spontaneous bowel motion) and depression (Leeds >6) were recorded in recent onset PD cases, and proposed non-motor
screening criteria applied.
Results: In 1,719 PD cases, mean age 68.6 years (SD 8.1), 65.5% male, mean disease duration 1.3 years (SD 0.9), 72.2%
were hyposmic, 43.3% had RBD, 22.1% depression, and 21.5% constipation. 11.6% of cases had no key non-motor features,
38.8% one, 32.1% two, 15.5% three, and 2.0% all four. Increasing numbers of non-motor features were associated with
younger age (p = 0.019), higher motor scores (p < 0.001), more postural instability gait difficulty (PIGD) (p < 0.001), greater
cognitive impairment (p < 0.001) and higher total non-motor burden (p < 0.001). Cases with hyposmia alone were younger
:
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(p < 0.001), had less severe cognitive (p = 0.006) and other non-motor features (p < 0.001). All screening criteria selected
younger patients (p = 0.001, p < 0.001), three of four greater overall non-motor burden (p = 0.005, p < 0.001), and inclusion
of RBD more cognitive impairment (p = 0.003, p = 0.001) and PIGD (p = 0.004, p = 0.001).
Conclusions: Varying sensitivity levels, and age and phenotype selectivity, are found when different non-motor screening
methods to detect prodromal PD are applied to an early clinical PD cohort.
Keywords: Parkinson disease, anosmia, rapid eye movement sleep behavior disorder, depression, constipation
INTRODUCTION
Several non-motor features of Parkinson’s disease
(PD) precede the initial motor features and there-
fore the diagnosis of PD, often by several years [1].
These include olfactory dysfunction, rapid eye move-
ment sleep behaviour disorder (RBD), constipation
and depression. Such early non-motor manifesta-
tions likely reflect extra-nigral pathology in the
olfactory bulb, lower brainstem nuclei and enteric
nerves, which precedes the characteristic dopamin-
ergic degeneration of the substantia nigra [2]. In the
absence of tissue or directed imaging biomarkers to
identify patients in this pre-diagnostic or pre-motor
phase, attention has increasingly focused on screen-
ing for these non-motor features, recognising their
potential significance in identifying and defining indi-
viduals ‘at risk’, in whom putative neuroprotective
agents might be tested [3–8].
Individual non-motor features are common in the
general population, with around a 20–40% preva-
lence for each of the following: anosmia, constipation
and depression, but only a minority of subjects with
these features will eventually develop PD [9]. RBD
affects less that 1% of the general population com-
pared to 15–46% of adults with PD, giving it much
higher specificity [10], but is limited by a prolonged
latency period prior to conversion [11]. Since multi-
ple concurrent non-motor features are more prevalent
in those with PD than in healthy controls [12–14],
combining non-motor features may improve screen-
ing specificity [4, 6, 15, 16]. Additional proposed
enrichment approaches include selecting those with
a family history of PD [4] and targeting an older age
group [7], with refinement by secondary screening
with transcranial sonography [3] or dopamine trans-
porter imaging [17].
However, while increasing the number of non-
motor features will undoubtedly improve specificity,
the sensitivity of existing non-motor screening meth-
ods to the presence of PD has not yet been established.
Testing the presence of non-motor markers in PD
cases after the motor diagnosis was reached would
help to clarify this issue.
Selectivity for disease subtype could also result
from particular screening approaches. There is
increasing recognition of disease heterogeneity in
PD, involving the presence and rate of progression
of motor and non-motor features. RBD is associ-
ated with PIGD (postural instability gait difficulty),
increased autonomic dysfunction and higher risk of
cognitive impairment and dementia [9]. Depression
is associated with poorer quality of life in PD [18],
PIGD and more rapid disease progression [19] and
constipation may reflect greater autonomic involve-
ment, at least of the enteric nervous system [20]. If
the utilisation of key non-motor features to detect
PD introduced a selectivity bias for PD subtype,
this would have implications for prognosis [21],
and therefore the design and interpretation of the
proposed treatment studies in pre-motor ‘at risk’ sub-
jects.
To address these issues we examined an early
clinical PD cohort for the prevalence and clinical
correlates of four key non-motor features known to
increase the risk of PD when present in asymptomatic
individuals. We then stratified the cohort according to
the fulfilment of several screening methods [3–6], to
rank the sensitivity of the proposed screening meth-
ods, and to assess their selectivity for disease severity
and classification.
METHODS
Study cohort
Study participants were enrolled in the recent
onset (diagnosed within the last 3.5 years) arm of
the Tracking Parkinson’s study, a prospective multi-
centre study (n = 72 sites) in the United Kingdom.
The full study protocol including inclusion/exclusion
criteria and definitions has been outlined in detail
[22]. In brief, cases with a clinical diagnosis of PD
D.M.A. Swallow et al. / Variation in Recent Onset Parkinson’s Disease 291
were recruited, fulfilling Queen Square Brain Bank
criteria, and supported by structural and functional
presynaptic dopaminergic neuroimaging performed
on clinical grounds. Cases diagnosed with vascular,
drug induced and atypical parkinsonism (multiple
system atrophy, progressive supranuclear palsy and
corticobasal degeneration) were excluded. Cases
with normal functional imaging performed after
study entry were excluded from analysis, as well
as cases with a revised diagnosis or emerging clin-
ical features which reduced diagnostic certainty. The
study was undertaken with written consent, with the
approval of the multi-centre regional ethics commit-
tee, and in compliance with national legislation and
the Declaration of Helsinki.
Measurement instruments
Olfaction was assessed using either the British ver-
sion of the 40-item University of Pennsylvania smell
identification test score (UPSIT) test (Sensonics Inc,
Haddon Heights, NJ, US), or the 16-item Sniffin’
Sticks test (Burghart Messtechnik, Wedel, Germany).
Hyposmia was defined as Sniffin’ Stick score at or
below the 10th centile [23] or UPSIT scores at or
below the 15th centile, corrected for age and sex [24].
RBD was assessed using the RBD screening ques-
tionnaire (RBDSQ), and a cut-off score of greater
than 4 applied [25]. Depression was scored if cases
had a Leeds/Hospital Anxiety and Depression Scale
score >6. Information on a previous diagnosis of
depression, as indicated in the Mini Environmental
Risk Questionnaire for Parkinson’s disease baseline
(MERQ-PD-B), was also collected. Constipation was
defined as less than one daily spontaneous bowel
motion [26].
Motor function was scored according to Part 3 of
the Movement Disorder Society unified PD rating
scale (UPDRS 3), indicating whether cases were in
an ‘on’ or ‘off’ state. Motor subtypes were defined
as tremor dominant, postural instability and gait
disorder, or indeterminate, according to UPDRS
3, using a predetermined formula [27]. Cognition
was assessed by the Montreal cognitive assessment
(MoCA), scored out of 30, and categorised using
diagnostic cut-offs as normal cognition (24–30), mild
cognitive impairment (22–23) or dementia (<22) [28,
29]. The 30 item non-motor symptom scale (NMSS),
which combines severity and frequency of symptoms,
was used following the established categories of mild
(1–20), moderate (21–40), severe (41–70) and very
severe (>70) [30]. Levodopa equivalent daily dose
(LEDD) dose was calculated using established for-
mulas [31]. Smoking status was measured using the
MERQ-PD-B and categorised as never (no regular
period of smoking, defined as 1 cigarette per day over
6 months), current, previous or passive (defined as
living with a smoker, not mutually exclusive of own
smoking status).
Screening methods
Screening criteria from four recent studies [3–6] of
prodromal PD were included. We selected these stud-
ies as representative of differing non-motor screening
approaches. Comparisons enabled the evaluation
of whether different screening criteria were differ-
entially sensitive in the detection of the various
subgroups of PD patients.
1. Hyposmia and/or family history [3]
Age 50 years and older, hyposmia, and/or a positive
history family for PD were the primary criteria, which
identified 468 (34.6%) ‘at risk’ subjects from an orig-
inal cohort of 1352 without PD, of whom 8 (1.7% of
those identified from primary screening) developed
PD during a median follow-up of 35.2 months.
2. Hyposmia (subset with family history of PD) [4]
Subjects without evidence of PD over 50 years old,
of whom approximately 50% had a first degree rel-
ative with PD, underwent olfactory assessment. The
second stage of screening, by dopamine transporter
imaging, found that the 669 cases with hyposmia
(13.4% of their 4, 999 subjects) were more likely
to have dopamine transporter (DAT) deficits (11%
of 203 assessed hyposmics, versus 1% of 100 nor-
mosmics) [17].
3. Hyposmia and/or RBD and/or depression [6]
Depression, RBD and hyposmia were used to
screen 698 subjects without PD, aged 50–80 years.
25 cases (3.6%) had all 3 features. The greater the
number of these 3 features that were present in an
individual patient, the higher the proportion with
additional features (from a set of 8 motor, and 15
additional non-motor features which occur in PD).
4. RBD and olfactory dysfunction [5]
Olfactory dysfunction had a diagnostic accuracy
of 82.4% for Lewy body disease, in patients with
polysomnography-confirmed idiopathic RBD at an
average duration of 2.4 years. The relative risk of
Lewy body disease in the lowest tertile of olfactory
dysfunction was 7.3 (confidence interval 1.8–29.6)
compared with the top two tertiles.
We tested these four screening algorithms, in our
cohort of recent onset clinical PD, to determine the
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sensitivity of each method. Accordingly, only cases
aged 50 years and older were included in our analysis,
since three of the four screening studies included sub-
jects by this age definition, while the fourth included
only 34 patients [5]. When assessing the screening
algorithm requiring hyposmia and/or RBD and/or
depression [6], depression was scored if individuals
had a Leeds score >6 or a self reported history of
depression (MERQ-PD), rather than a Leeds score >6
alone, in order to more closely match the definition
of depression utilised in that study. A supplementary
analysis was also performed using additional vari-
ables, identified from a meta-analysis, which double
the PD risk (family history, never smokers and con-
stipation) [1].
Statistical analysis
Cases with a revised diagnosis or emerging clin-
ical features suggesting an alternative diagnosis,
at their latest follow up visit (average 3.5 years)
were excluded. General linear modelling was used
to assess variables across non-motor categories,
adjusting for multiple covariates (age, sex and dis-
ease duration) with heterogeneity p-values calculated
when the number of categories was more than two.
In the case of motor subtype analyses multino-
mial logistic regression was used with the Tremor
Dominant category as the baseline. For the cate-
gorised MoCA analyses ordered logistic regression
was used. For age, disease duration, UPDRS 3 and
NMSS total, linear regression was used, while for
analyses of sex and whether dopamine imaging
was performed, logistic regression was used. The
main analysis was performed using a complete case
approach. An additional sensitivity analysis was per-
formed imputing missing outcome and exposure data.
Where sum scores of scales were used in analy-
sis we first calculated expected scores when at least
80% of the questions in these scales were answered.
Any remaining missing data was imputed using the
chained equation approach to multiple imputation
creating 10 imputed datasets. Adjustedpvalues <0.05
were considered significant. IBM SPSS Statistics for
Windows, Version 22.0, Armonk, NY and STATA
version 13 was used for statistical analysis.
RESULTS
Out of 2,006 cases recruited to the study, and fol-
lowed to a mean of 3.5 years (SD 1.2) from diagnosis,
287 cases were excluded due to a revised diagno-
sis (n = 22), disease duration greater than 3.5 years
(n = 6), age less than 50 (n = 91), missing age (n = 1),
or with one or more features atypical for PD (n = 167)
(Fig. 1). There were thus 1,719 recent onset cases
available for analysis, whose demographic, motor
and non-motor characteristics are shown in Table 1.
Of the four non-motor features of interest, hyposmia
was present in 72.2%, RBD in 43.3%, depression in
22.1%, and constipation in 21.5% of cases. Restricted
to 1324 cases with complete data on all four non-
motor features, 11.6% of cases had none of the four
features; increasing the required number of non-
motor features identified smaller numbers of cases,
from one non-motor symptom in 38.8% of cases,
through to four non-motor symptoms in 2.0% of cases
(Table 2). The proportion of cases with individual and
combination features highlighted wide variations in
patterns of non-motor involvement (Fig. 2).
Increasing non-motor burden was associated with
a higher UPDRS motor score (p < 0.001) including
more PIGD (p < 0.001), a higher total NMSS score
(p < 0.001) and a greater proportion with MCI and
dementia (p < 0.001) (Table 2). Cases with multiple
non-motor features were also significantly younger
(p = 0.019), than those without these features.
Considering the 38.8% of cases with only one
non-motor feature, there were significant differences
Fig. 1. Disposition of cases recruited to the study, and rea-
sons for exclusion, to define the main analysis dataset of 1719
patients.
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Table 1
Baseline demographic, motor and non-motor characteristics of
1719 recent onset Parkinson’s disease cases
Characteristic Result
Age in years 68.6 (8.1)
Male sex 1125 (65.5%)
Disease duration in years 1.3 (0.9)
NMSS total 31.6 (25.4)
Non-motor feature
Hyposmia 1041 (72.2%)
RBD 694 (43.3%)
Constipation 358 (21.5%)
Depression 364 (22.1%)
Smoking
Current 60 (4.0%)
Never 509 (33.8%)
Previous 582 (38.6%)
Passive 356 (23.6%)
Family history
One member affected 264 (15.5%)
>1 member affected 65 (3.8%)
UPDRS 3 22.7 (12.2)
Motor subtype
TD 740 (47.2%)
PIGD 626 (39.9%)
Indeterminate 201 (12.8%)
Hoehn & Yahr stage, median (IQR) 2 (1 − 2)
MoCA
Normal 1154 (73.0%)
MCI 195 (12.3%)
Dementia 231 (14.6%)
Antiparkinson medication (current)
Drug naı¨ve 167 (9.7%)
Levodopa 1102 (64.3%)
Dopamine agonist 520 (30.3%)
MAOB Inhibitor 415 (24.2%)
LEDD 294 (206)
Dopamine imaging performed 403 (27.8%)
Data are mean (standard deviation) or number (percentage) unless
otherwise stated. NMSS = non motor symptom scale, RBD = rapid
eye movement sleep behaviour disorder, UPDRS 3 = Movement
Disorder Society unified Parkinson’s disease rating scale part 3,
TD = tremor dominant, PIGD = postural instability gait difficulty,
IQR = interquartile range, MoCA = Montreal cognitive assess-
ment, MCI = mild cognitive impairment, MAOB = monoamine
oxidase type B, LEDD = levodopa equivalent daily dose.
in age (p < 0.001), cognition (p = 0.006), and total
NMSS (p < 0.001), according to which non-motor
feature was present (Table 3). Patients with isolated
depression were most impaired, with the greatest cog-
nitive and non-motor severity, compared to patients
with other isolated non-motor features. Those with
isolated hyposmia were youngest, with the least cog-
nitive impairment and overall non-motor burden,
compared to patients with other isolated non-motor
features (Table 3).
The proportion of recent onset patients identi-
fied using the four proposed screening criteria are
detailed in Table 4. One or more of hyposmia, RBD or
depression identified the largest proportion (90.6%)
of the cohort [6]. There were significant differences in
the clinical characteristics identified by the different
screening algorithms (Table 4). All the screen-
ing algorithms identified younger cases (p = 0.001,
p < 0.001), three [3, 5, 6] of four methods greater total
non-motor burden (p = 0.005, p < 0.001), while two of
the four methods [5, 6] preferentially selected for the
PIGD subtype (p = 0.004, p = 0.001) and greater cog-
nitive impairment (p = 0.003, p = 0.001). Hyposmia
and/or depression and/or RBD [6] additionally identi-
fied greater motor impairment (p = 0.003). Hyposmia
and RBD [5] also identified males (p < 0.001), those
with a longer disease duration (p = 0.007), and a
greater proportion with the indeterminate subtype
(p = 0.002). Using factors which were shown to dou-
ble PD risk [1], identified 55.4% of our cohort, and
when key non-motor features were added to these
variables, the rate increased to a maximum of 94.5%
(Supplementary Table 1).
After calculating expected scores for those who
answered 80% or more of the questions, missing data
on PD outcomes ranged from only 1.2% (UPDRS 3
and MoCA) to 3.8% (motor subtype). For our four
non-motor features, missing data ranged from 2.5%
(RBD) to 12.4% (hyposmia). In order to address this
further, we repeated our analysis, undertaking miss-
ing data imputation (Supplementary Tables 2–4). The
p-values of the complete case analysis and analy-
sis using data imputation were very similar, with
only one difference in statistical significance (inde-
terminate phenotype Table 2 versus Supplementary
Table 2).
DISCUSSION
Our study is, to our knowledge, the first to analyse
proposed non-motor screening methods for prodro-
mal PD in an early clinical PD cohort as a ‘best case
scenario’ for the utility of these screening methods,
and has two main findings.
First, we found that non-motor screening algo-
rithms aiming for high specificity by combining
non-motor features had variable sensitivity in detect-
ing those with early clinical PD. 11.6% of PD cases,
diagnosed on average 1.2 years earlier, had none
of the four key non-motor features, with 38.8%
having only one such non-motor feature. In turn,
the proposed non-motor screening methods detected
between 31.9% and 90.6% with early clinical PD.
Second, we found evidence that both the number
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Table 2
Clinical correlates in 1324 recent onset Parkinson’s disease cases with data on all four non-motor features according to the number of key
non-motor features
Variable Number of non-motor features
None One Two Three Four Unadjusted Adjusted
n = 154 n = 513 n = 425 n = 205 n = 27 p-value p-value
(11.6%) (38.8%) (32.1%) (15.5%) (2.0%)
Age 69.9 (7.6) 68.4 (8.3) 67.6 (7.7) 67.7 (8.0) 67.1 (7.6) 0.032 0.019a
Male Sex 101 (65.6%) 322 (62.8%) 282 (66.4%) 137 (66.8%) 20 (74.1%) 0.60 0.55b
Disease duration 1.2 (0.9) 1.3 (0.9) 1.4 (0.9) 1.4 (1.0) 1.6 (0.9) 0.23 0.16c
UPDRS 3 19.5 (10.8) 21.7 (12.1) 21.5 (11.4) 25.2 (11.6) 28.2 (10.0) <0.001 <0.001d
Motor subtype
TD 87 (61.3%) 260 (53.4%) 179 (44.8%) 71 (36.4%) 10 (40.0%)
PIGD 41 (28.9%) 174 (35.7%) 164 (41.0%) 98 (50.3%) 13 (52.0%) <0.001 <0.001d
Indeterminate 14 (9.9%) 53 (10.9%) 57 (14.3%) 26 (13.3%) 2 (8.0%) 0.050 0.036d
MoCA
Normal 109 (78.4%) 386 (80.4%) 284 (72.6%) 135 (69.6%) 16 (64.0%) 0.007 <0.001d
MCI 15 (10.8%) 46 (9.6%) 58 (14.8%) 27 (13.9%) 3 (12.0%)
Dementia 15 (10.8%) 48 (10.0%) 49 (12.5%) 32 (16.5%) 6 (24.0%)
NMSS Total 17.0 (12.1) 23.9 (18.0) 33.2 (22.7) 49.4 (30.9) 60.6 (33.1) <0.001 <0.001d
Dopamine imaging performed 46 (34.6%) 121 (27.3%) 108 (30.2%) 47 (26.7%) 8 (33.3%) 0.47 0.14d
Data are mean (standard deviation) or number (percentage). UPDRS 3 = Movement Disorder Society unified Parkinson’s disease rating scale,
TD = tremor dominant, PIGD = postural instability gait difficulty, MoCA = Montreal cognitive assessment, MCI = mild cognitive impairment,
NMSS = non motor symptom scale. aAdjusted for disease duration and sex, bAdjusted for age and disease duration, cAdjusted for age and
sex, dAdjusted for age, sex and disease duration.
Fig. 2. Frequency of individual and combinations of non-motor features in 1324 recent onset Parkinson’s disease cases with data on all four
non-motor features
and type of non-motor feature included in screen-
ing methods may introduce selectivity for particular
clinical characteristics.
Incremental increases in disease severity were
seen as the number of key non-motor features
increased from none to four. Cases with three or
more non-motor features were significantly younger,
more likely to have PIGD, and had more severe
Parkinson’s, both from the motor and non-motor
viewpoint. Also, they were more likely to have
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Table 3
Clinical correlates in 513 recent onset Parkinson’s disease with complete case data and only one non-motor feature
Variable Hyposmia only RBD only Constipation only Depression only Unadjusted Adjusted
n = 375 n = 83 n = 33 n = 22 p-value p-value
(73.1%) (16.2%) (6.4%) (4.3%)
Age 67.3 (7.8) 70.4 (7.9) 73.6 (9.3) 70.1 (10.9) <0.001 <0.001a
Male Sex 234 (62.4%) 51 (61.4%) 26 (78.8%) 11 (50.0%) 0.17 0.19b
Disease duration 1.3 (0.9) 1.4 (0.9) 1.5 (0.9) 1.2 (1.0) 0.42 0.54c
UPDRS 3 20.6 (11.3) 23.4 (12.7) 25.1 (15.7) 27.6 (15.1) 0.008 0.073d
Motor subtype
TD 200 (56.0%) 37 (48.1%) 13 (41.9%) 10 (45.5%)
PIGD 116 (32.5%) 34 (44.2%) 16 (51.6%) 8 (36.4%) 0.11 0.32d
Indeterminate 41 (11.5%) 6 (7.8%) 2 (6.5%) 4 (18.2%) 0.64 0.62d
MoCA
Normal 289 (82.1%) 60 (80.0%) 26 (81.3%) 11 (52.4%) 0.008 0.006d
MCI 36 (10.2%) 3 (4.0%) 4 (12.5%) 3 (14.3%)
Dementia 27 (7.7%) 12 (16.0%) 2 (6.3%) 7 (33.3%)
NMSS Total 20.9 (14.9) 26.7 (17.6) 28.2 (15.8) 58.0 (30.8) <0.001 <0.001d
Dopamine imaging performed 85 (26.3%) 18 (25.7%) 11 (35.5%) 7 (35.0%) 0.60 0.34d
Data are mean (standard deviation) or number (percentage). UPDRS 3 = Movement Disorder Society unified Parkinson’s disease rating scale,
TD = tremor dominant, PIGD = postural instability gait difficulty, MoCA = Montreal cognitive assessment, MCI = mild cognitive impairment,
NMSS = non motor symptom scale. aAdjusted for disease duration and sex, bAdjusted for age and disease duration, cAdjusted for age and
sex, dAdjusted for age, sex and disease duration.
dementia. All of these differences remained after cor-
recting for confounding variables. These findings are
consistent with several other studies, encompassing
recent onset PD cases, and screening paradigms in
‘at risk’ cases. In two studies in newly diagnosed PD,
a worsening motor score was found with increasing
numbers of non-motor features [13, 32]. Others have
also noted the association between increasing non-
motor features and PIGD [13, 33]. In the TREND
screening study, one or more of the three non-motor
screening features correlated with a broader range of
non-motor features, and with prodromal motor symp-
toms [6]. A similar correlation was present when
hyposmia and RBD were analysed against other non-
motor and potential motor disease markers, in the
PREDICT-PD study [7]. However, such associations
are not universal: in the ONSET-PD study, 60%
of patients had few, minimally disabling non-motor
symptoms, and they did not differ from the remaining
40% with a high non-motor burden, in terms of either
motor severity, or motor phenotype [14]. However,
the overall balance of evidence favours concurrence
of selected non-motor features with other non-motor
features, greater motor severity and PIGD.
In addition to the number of key non-motor fea-
tures included in screening algorithms, the type of
non-motor feature selected for inclusion may also
affect the clinical characteristics of cases identified.
‘Hyposmia only’ cases had milder overall non-
motor burden than cases with only one of the other
key non-motor features. This matches the TREND
results, in which hyposmic subjects had a lower num-
ber of additional prodromal PD features (including
other non-motor, motor and neuropsychiatric fea-
tures) compared to those with depression and RBD
[3]. The low non-motor severity is also in keeping
with the PARS study in which a very small proportion
of hyposmic cases had multiple non-motor features
[4]. Depression, in contrast, emerged as a marker for
a particularly severe overall non-motor burden, con-
sistent with previous observations [14]. Strikingly,
only 52.4% of those with depression were cognitively
normal, in contrast to 82.1% of those with hypos-
mia alone, again consistent with previous findings
[34], but which may in part be explained by “pseu-
dodementia” due to lack of motivation to engage in
cognitive tests [35].
Overall, the unifying feature across screening
methods using these key non-motor features was their
selectivity for younger patients, and when RBD was
included, the PIGD subtype and greater cognitive
impairment. The sensitivity and selectivity levels for
particular disease characteristics need to be taken into
account when considering the application of screen-
ing methods and the generalisability of observational
or therapeutic studies that have used these methods.
However, there appears to be scope for improving
sensitivity by adding additional screening variables.
For example, additional PD risk variables emerging
from meta-analysis (family history of tremor, and/or
never smoking, and/or constipation) as doubling the
risk of future PD [1] appeared sensitive, identifying
296
D
.M
.A.Swallow
et
al./V
a
riation
in
RecentO
nsetP
a
rkinson’sD
isease
Table 4
Proportion and clinical characteristics of recent onset Parkinson’s disease patients with complete case data identified by four different screening algorithms
Hyposmia and/or Hyposmia in enriched Hyposmia and/or RBD Hyposmia and RBD [5]
family history [3] cohort (50% family history) [4] and/or depression [6]
Yes No Adjusted Yes No Adjusted Yes No Adjusted Yes No Adjusted
n = 1182 n = 315 p-value n = 422 n = 176 p-value n = 1414 n = 146 p-value n = 432 n = 922 p-value
(79.0%) (21.0%) (70.6%) (29.4%) (90.6%) (9.4%) (31.9%) (68.1%)
Age 67.5 (7.8) 70.7 (7.9) <0.001a 67.5 (7.9) 70.1 (7.9) <0.001a 68.0 (7.9) 70.6 (8.1) <0.001a 67.3 (7.5) 68.6 (8.1) 0.001a
Male Sex 764 (64.6%) 215 (68.3%) 0.40b 273 (64.7%) 112 (63.6%) 0.54b 915 (64.7%) 103 (70.5%) 0.23b 312 (72.2%) 571 (61.9%) <0.001b
Disease duration 1.4 (0.9) 1.3 (0.9) 0.29c 1.4 (0.9) 1.3 (0.9) 0.080c 1.4 (0.9) 1.3 (0.9) 0.34c 1.4 (0.9) 1.3 (0.9) 0.007c
UPDRS 3 22.3 (12.0) 22.1 (12.0) 0.19d 21.4 (11.5) 23.3 (13.0) 0.15d 22.7 (12.3) 20.3 (11.6) 0.003d 22.8 (11.5) 21.8 (11.9) 0.17d
Motor subtype
TD 523 (48.2%) 148 (50.9%) 182 (46.3%) 83 (52.2%) 593 (45.4%) 77 (57.0%) 167 (41.4%) 449 (51.7%)
PIGD 424 (39.0%) 111 (38.1%) 0.27d 160 (40.7%) 60 (37.7%) 0.20d 545 (41.7%) 44 (32.6%) 0.004d 176 (43.7%) 326 (37.5%) 0.001d
Indeterminate 139 (12.8%) 32 (11.0%) 0.32d 51 (13.0%) 16 (10.1%) 0.18d 168 (12.9%) 14 (10.4%) 0.13d 60 (14.9%) 94 (10.8%) 0.002d
MoCA
Normal 817 (74.8%) 220 (75.9%) 0.069d 303 (75.9%) 120 (75.5%) 0.46d 957 (72.9%) 106 (79.7%) 0.003d 287 (71.0%) 660 (77.5%) 0.001d
MCI 138 (12.6%) 26 (9.0%) 51 (12.8%) 21 (13.2%) 162 (12.3%) 15 (11.3%) 59 (14.6%) 95 (11.2%)
Dementia 137 (12.6%) 44 (15.2%) 45 (11.3%) 18 (11.3%) 193 (14.7%) 12 (9.0%) 58 (14.4%) 97 (11.4%)
NMSS Total 32.5 (26.1) 27.3 (21.0) 0.005d 33.0 (24.3) 31.6 (26.4) 0.82d 34.0 (26.4) 17.7 (12.5) <0.001d 40.2 (28.7) 26.9 (21.5) <0.001d
Dopamine 281 (27.9%) 89 (32.5%) 0.004d 114 (31.2%) 47 (30.1%) 0.65d 329 (27.4%) 44 (34.4%) 0.008d 111 (30.2%) 231 (29.1%) 0.72d
imaging
performed
Data are mean (standard deviation) or number (percentage). UPDRS 3 = Movement Disorder Society unified Parkinson’s disease rating scale part 3, TD = tremor dominant, PIGD = postural
instability gait difficulty, MoCA = Montreal cognitive assessment, MCI = mild cognitive impairment, NMSS = non motor symptom scale. aAdjusted for disease duration and sex, bAdjusted for age
and disease duration, cAdjusted for age and sex, dAdjusted for age, sex and disease duration.
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55.4% of our cohort before any of the remaining key
non-motor features were added. Adding those non-
motor features increased sensitivity to 94.5%. The
NMSS may be worthy of exploration given the rela-
tionship we found between the four key non-motor
features and the total NMSS score, and the relatively
high cost of olfaction testing compared to a question-
naire. Phenotypic selectivity could be addressed by
inclusion of risk markers. Genetic variation for exam-
ple may in part determine clinical heterogeneity in
PD [36]. However, genetic risk classification showed
only incremental effects on classification accuracy
beyond the clinical variables, while constipation and
smoking were not found to be additive in a diag-
nostic model comparing PD and controls [37]. More
recently, probability methodology for prodromal PD
has been developed [26], encompassing a spectrum
of predictive markers including both background risk
(genetic and environmental) and diagnostic marker
testing (including non-motor features) expressed as
likelihood ratios.
It is important that our findings are representative
of the non-motor profile in an early PD population.
The rank order with each non-motor feature was com-
parable to another recent onset cohort using similar
methods [38]. As in other cohort studies, hyposmia
was the most prevalent of the non-motor features
[13, 14, 38] and accounted for over half of those
with only one non-motor feature. The rate of other
non-motor features was also similar to other cohort
studies, but with some variation; depression was more
common in one study [39], and RBD less common
in another [14]. Some variation between studies is
expected given the heterogeneity and different sensi-
tivity of measurement techniques, as well as varying
disease durations, and would likely influence the
exact proportions with none, one or combinations of
non-motor features found in other studies, but overall
the similarities across studies appear to be sufficient.
Potential limitations of the study relate to the
presence and persistence of non-motor features.
Improvement in non-motor features by antiparkin-
sonian drug therapy may have reduced the sensitivity
of the screening methods in our cohort, given that
only 9.7% of our PD cases were drug naı¨ve. However,
no differences in the severity of non-motor features
were found in treated versus untreated early (<5
years) PD patients in another study [32], which con-
cluded that non-motor features were influenced more
by the underlying disease process than dopaminergic
replacement. The second aspect is the assumption that
the key non-motor symptoms are persistent, which is
almost certainly true for hyposmia, but less accurate
for depression and RBD which are known to fluctu-
ate. Furthermore given that our cohort all manifested
motor PD, we cannot be sure that those people screen-
ing positive for these non-motor symptoms exhibited
them before the onset of their motor disorder; i.e.
they could be used to predict the onset of motor PD
in these individuals. Another consideration relates to
diagnostic accuracy, and whether a higher propor-
tion of our cases with few non-motor features could
have an alternative diagnosis than PD, often referred
to as subjects without evidence of dopaminergic
deficit (SWEDD). However, we found no difference
in the proportion of patients who had confirmatory
presynaptic dopaminergic imaging according to the
number of the four key non-motor features that were
present. In addition, there was no evidence of a
lower rate of non-motor features in SWEDD cases in
another recent cohort study [40]. While we excluded
cases with revised diagnoses, or emerging features
suggesting an alternative diagnosis, in keeping with
all population studies we cannot exclude the possibil-
ity that a small proportion of cases may have atypical
parkinsonian disorders.
In conclusion, screening methods based largely on
non-motor features show varying levels of sensitiv-
ity even in early PD, and are generally selective for
younger patients and those with a PIGD motor phe-
notype. Awareness of these factors is important as we
work further to enhance screening methodologies.
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